Drugs Made In America Acquisition Corp. financial data

Symbol
DMAA, DMAAR, DMAAU on Nasdaq
Location
2 Pelican Dr., Fort Lauderdale, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 18, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 8.1 %
Debt-to-equity -103 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.5M shares
Common Stock, Shares, Outstanding 10.5M shares
Common Stock, Value, Issued 1.05K USD

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 264K USD +82%
Operating Income (Loss) -264K USD -82%
Nonoperating Income (Expense) 2.45M USD
Net Income (Loss) Attributable to Parent 2.18M USD

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 28.2K USD
Assets 238M USD
Accrued Liabilities, Current 303K USD
Liabilities, Current 457K USD
Liabilities 7.36M USD
Retained Earnings (Accumulated Deficit) -6.72M USD
Stockholders' Equity Attributable to Parent -7.33M USD -4345%
Liabilities and Equity 238M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 220M shares
Common Stock, Shares, Issued 10.5M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 717 USD -65.8%
Preferred Stock, Shares Authorized 1M shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares